Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adherium Taps Nektar’s Former BD Exec To Head New North America Unit

This article was originally published in Clinica

Executive Summary

Adherium, the developer of the SmartInhaler technology for improving medication adherence in patients with chronic respiratory disorders, has appointed James Hattersley senior vice-president of business development, North America. Hattersley joins from US pharm firm Nektar Therapeutics, where he held a similar position. He will leverage his experience in identifying opportunities for commercial partnerships and strategic alliances to expand Adherium’s presence in the US and Canada. His appointment coincides with the opening of the company’s new San Francisco, California subsidiary serving that region, Adherium North America, Inc. Australian Stock Exchange-listed Adherium’s Smartinhaler platform comprises a range of approved Smartinhaler medication sensors which attach to prescription inhalers, and the SmartinhalerLive software, which integrates the data from the Smartinhalers into a usable form via communications protocols, mobile applications and cloud based software. The company teams up with pharma players, an example being AstraZeneca, with whom Adherium entered a long-term partnership last year to supply new devices and sensors to incorporate within global patient support programs for patients with COPD and asthma.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel